Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Songjiang Ma, President of Gyre Therapeutics, sold 4,000 shares of common stock on February 19th and 20th, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Songjiang Ma, the President of Gyre Therapeutics, sold 2,000 shares of common stock on February 19, 2025, at a weighted average price of $12.29 per share.
- An additional 2,000 shares were sold on February 20, 2025, at a weighted average price of $12.40 per share.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Following these sales, Mr. Ma directly owns no shares, but his spouse indirectly owns 2,863,260 shares.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing related to insider stock sales under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment, but insider selling can sometimes be viewed with caution.
Industry Context
Insider selling can sometimes be interpreted negatively by the market, but the use of a pre-arranged 10b5-1 trading plan often mitigates this concern as it indicates the sales were planned in advance and not based on current, non-public information.
Stakeholder Impact
- Shareholders may react to the news of insider selling, although the existence of a 10b5-1 plan may lessen any negative impact.
Key Dates
| Date | Description |
|---|---|
| 09/13/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 02/19/2025 | Date of first stock sale |
| 02/20/2025 | Date of second stock sale |
| 02/21/2025 | Date of Form 4 filing |
Keywords
Gyre Therapeutics, Songjiang Ma, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, GYRE
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.